Nebenwirkungen · Eporatio
Eporatio 1,000 IU/0.5 ml solution for injection in pre-filled syringe Eporatio 2,000 IU/0.5 ml solution for injection in pre-filled syringe Eporatio 3,000 IU/0.5 ml solution for injection in pre-filled syringe Eporatio 4,000 IU/0.5 ml solution for injection in pre-filled syringe Eporatio 5,000 IU/0.5 ml solution for injection in pre-filled syringe Eporatio 10,000 IU/1 ml solution for injection in pre-filled syringe Eporatio 20,000 IU/1 ml solution for injection in pre-filled syringe Eporatio 30,000 IU/1 ml solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 9
HOS-210274 · Präparat HOS-154485
Description of selected adverse reactions In patients with chronic renal failure, neutralising anti-erythropoietin antibody-mediated pure red cell aplasia (PRCA) associated with epoetin theta therapy has been reported in post marketing setting. If PRCA is diagnosed, therapy with epoetin theta must be discontinued and patients should not be switched to another recombinant epoetin (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-09-27T14:04:00Z · SHA-256 58cbb3874f2c797e6432a5eaa290c9f92472db53e0c8f96f2ce29308109e3afb · Passage e7854af36b5baf4828bc70bb29c7132b57964a098281738ae82186fb84508ea7 · Zeichen 2624–3024 im Abschnitt